69 results about "Angiotensin-converting enzyme" patented technology

The invention discloses a mulberry leaf antihypertensive active peptide as well as a preparation method and application thereof. According to the method, mulberry leaves are used as raw materials to prepare mulberry leaf albumin, enzymolysis parameters of enzymolysis time, pH, enzyme-substrate ratio and substrate concentration are optimized through a single factor experiment and an orthogonal experiment, and optimal enzymolysis conditions for preparing the ACE inhibitory peptide crude product are provided; the high-activity ACE inhibitory peptide is identified through further purification, polypeptide sequence determination and virtual screening, the ACE inhibitory peptide has extremely high solubility and good ACE inhibitory activity, and the IC50 values of the two peptides VPSCFDLTGK and RLPDFHGL with the highest activity are 8.23 [mu] mol / L (8.765 [mu] g / mL) and 23.01 [mu] mol / L (23.58 [mu] g / mL) respectively. The active peptide can be used as an angiotensin converting enzyme inhibitory peptide, and achieves the purpose of reducing blood pressure by inhibiting ACE activity.

The invention relates to an in-vitro detection reagent, in particular to a reagent and a kit for determining angiotensin converting enzyme and a preparation method of the reagent and the kit. The reagent comprises a substrate and an enzyme activity regulator, the substrate can be catalyzed by angiotensin converting enzyme in a to-be-detected sample to react and generate a detectable signal, the strength of the detectable signal is related to the activity of the angiotensin converting enzyme in the sample, the enzyme activity regulator comprises at least one of three metal ions, namely Zn < 2 + >, Co < 2 + > and Mn < 2 + >, and the concentration of the enzyme activity regulator is more than 10 times of the physiological concentration of metal ions in serum. By optimizing the reagent formula, the detection reaction rate is stabilized, and the analysis sensitivity, precision and accuracy are improved.

The application discloses a polypeptide-based anti-fouling electrochemical sensor and a construction method and application thereof. In the application, cysteine is used as an anchoring end, an alpha-helix structure is formed by inserting polyproline to give a supporting effect to the whole peptide, then angiotensin converting enzyme inhibitory peptide (KSRE) and alpha-glucosidase inhibitory peptide (EKDER) are used as branches to prepare the anti-fouling polypeptide. The anti-fouling polypeptide has a better anti-fouling effect than other anti-fouling polypeptides, and the working electrode is modified by the anti-fouling polypeptide to prepare an anti-fouling electrochemical aptamer sensor for detecting AFB1, so that the anti-pollutant interference effect of the sensor can be greatly improved, the accuracy and sensitivity of AFB1 detection can be improved, and the anti-fouling electrochemical aptamer sensor has a wide application prospect.

The invention discloses an ACE (angiotensin converting enzyme) inhibitory peptide with antihypertensive activity and application thereof, and belongs to the technical field of active peptide biology, amino acid sequences of the ACE inhibitory peptide are EYPVK and SYPVK, the two peptides are obtained through module replacement design, the ACE inhibitory activity of the two peptides is remarkably improved compared with that of an original peptide LYPVK, IC50 values are respectively reduced to 14.82 + / -0.82 mu M and 12.83 + / -0.79 mu M from 117.14 + / -1.40 mu M, and the inhibitory activity is improved by 13.5% and 25.1%. Molecular simulation analysis shows that the interaction force between the two and ACE is stronger, and a potential modular effect exists between sequences. Besides, the polypeptide has remarkable blood pressure lowering activity on human umbilical vein endothelial cells, plays a role by regulating release of NO and ET-1, has the activity superior to that of original peptides, has the advantages of good digestive enzyme stability, small molecular weight and good water solubility, and is suitable for developing related products for lowering blood pressure.

The application discloses selenium-containing chickpea peptides, a preparation method thereof and application of the selenium-containing chickpea peptides in preparation of blood pressure lowering drugs, and belongs to the technical field of bioactive peptides. Selenium-enriched Bacillus natto is used to ferment chickpeas to obtain selenium-containing chickpea protein hydrolysate, and then fermentation conditions are optimized and quantitative peptidomics technology is used to obtain selenium-containing chickpea peptides PQM and PQML. Experiments prove that the selenium-containing chickpea peptides have good in-vivo stability, bioavailability and blood pressure lowering activity, have an effect of inhibiting angiotensin converting enzyme (ACE) activity, and have potential for preventing or treating hypertension.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

The invention belongs to the technical field of biological detection, and discloses a method for simultaneously detecting large fragment deletion of ACE (Angiotensin Converting Enzyme) and CYP2D6 genes. The kit provided by the invention can simultaneously amplify a plurality of target fragments (such as CYP2D6 gene deletion long fragments and ACE gene deletion short fragments) with obvious size difference under the same system, so that the experimental operation steps are reduced by half, and the detection time is obviously shortened; the reagent cost is saved, and the use amount of an electrophoresis reagent is reduced by half; operation links are reduced, and the risk of sample confusion is reduced.

Angiotensin-converting enzyme 2 (ACE2) has been identified as a specific receptor for severe acute respiratory syndrome coronavirus (SARS-CoV-1) and several beta-group coronaviruses, including SARS-CoV-2, the causative agent of the recent global pandemic COVID-19, and the low-pathogenic coronavirus HCoV-NL63, a member of the alpha-coronavirus group. The viral spike protein (S) of the viral envelope has been identified as a viral receptor that binds to ACE2 and initiates the viral replication cycle. The present invention provides ACE2 and its mutant or variant forms, as well as viral or non-viral vectors thereof. Methods for treating viral infections in human subjects using such mutant or variant forms are also provided.

The invention discloses a preparation method of spirulina functional polypeptide. The polypeptide provided by the invention has an amino acid sequence shown as a sequence 1 in a sequence table. The functional polypeptide (YSDITRPG) found from spirulina is a purely natural, non-toxic and harmless microbial source substance, has a remarkable ACE (angiotensin converting enzyme) inhibition effect and a colon cancer cell inhibition effect, can be used as an antihypertensive component, can also be used as an active component of a colon cancer medicine, is non-toxic, meets the requirements of medicinal preparation development, and has a wide application prospect. Meanwhile, the product can be easily added into various health-care foods as a functional factor, and has a good market prospect in medicine and food industries.

Disclosed are a peptide, an antibody, or an antigen-binding fragment thereof, which specifically binds to an ACE2 (angiotensin-converting enzyme 2) receptor, and a composition for preventing SARS-CoV-2, the composition comprising the same. The peptide includes at least one peptide sequence selected from a group consisting of [SEQ ID NO: 1] GHPVNSVLLDF, [SEQ ID NO: 2] GHPRVNVGGDF, [SEQ ID NO: 3] GVLGPRLLIDY and [SEQ ID NO: 4] DGPINRTTIDY.

The invention belongs to the field of microbial fermentation, and particularly relates to a method for fermenting celery by lactobacillus plantarum. The lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36518, and the preservation date is November 06, 2025. The lactobacillus plantarum has acid resistance, bile salt resistance, artificial gastrointestinal fluid tolerance and angiotensin converting enzyme inhibitory activity. The invention discloses application of lactobacillus plantarum in preparation of celery fermented products. The contents of total phenols and total flavonoids in the celery juice fermented by lactobacillus plantarum are greatly increased, and the angiotensin converting enzyme inhibition rate, the DPPH clearance rate and the ABTS clearance rate of the celery leaf fermented juice are obviously increased compared with those of the celery leaf fermented juice without fermentation. According to the method, the polyphenol content and the biological activity of the celery juice are improved through metabolism, and the celery juice has the potential of resisting oxidation and reducing blood pressure and has the prospect of being developed into functional fermented food.

The invention discloses a preparation method and application of an edible grass leaf source active peptide with ACE (angiotensin converting enzyme) inhibitory activity, and belongs to the technical field of biological active peptides. The preparation method comprises the following steps: firstly, extracting azolla filliculoidas protein from azolla filliculoidas powder by adopting an ultrasonic-assisted alkali-solution and acid-isolation method; dissolving a certain amount of rumex hanus powder in distilled water, adjusting the pH value of the solution, carrying out water bath preheating, and adding neutral protease for enzymolysis; and carrying out ultrafiltration and DEAE Sepharose FF anion gel column separation on the obtained enzymolysis product to obtain the azolla filliculoidas source active peptide with efficient angiotensin converting enzyme inhibitory activity. The preparation method is simple in process, mild in condition and easy to popularize, the obtained active peptide has wide application prospects in development of functional food, health care products and antihypertensive drugs, and effective utilization and value improvement of azolla filliculoidas protein resources are facilitated.

The present disclosure relates to the use of angiotensin-converting enzyme and / or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.

The application provides a polypeptide with angiotensin converting enzyme inhibitory activity and a preparation method and application thereof, and relates to the technical field of active peptide preparation. The abalone is pulverized, a complex enzyme is added for primary enzymolysis, and then a specific protease mixture containing prolyl endopeptidase, chymotrypsin and protease K is added for two-step enzymolysis, so that the obtained polypeptide solution has high ACE inhibitory activity. The obtained polypeptide is analyzed and screened to obtain polypeptides with amino acid sequences as shown in SEQ ID NO. 1-5. The polypeptide has high ACE inhibitory activity, and the IC 50 0.05mg / mL-0.40mg / mL, and therefore can play a blood pressure lowering effect as an angiotensin converting enzyme inhibitor.

Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.

This invention discloses a mulberry leaf antihypertensive active peptide, its preparation method, and its application. Using mulberry leaves as raw material, this invention prepares mulberry leaf albumin. Enzymatic hydrolysis parameters, including hydrolysis time, pH, enzyme-to-substrate ratio, and substrate concentration, were optimized through single-factor and orthogonal experiments, providing optimal hydrolysis conditions for preparing crude ACE-inhibiting peptides. Further purification, peptide sequencing, and virtual screening identified highly active ACE-inhibiting peptides with strong solubility and good ACE-inhibiting activity. The two peptides with the highest activity, VPSCFDLTGK and RLPDFHGL, showed the highest IC50 values. 50 The values ​​were 8.23 ​​μmol / L (8.765 μg / mL) and 23.01 μmol / L (23.58 μg / mL), respectively. These bioactive peptides can act as angiotensin-converting enzyme inhibitory peptides, thereby lowering blood pressure by inhibiting ACE activity.

The invention discloses lactobacillus helveticus IMAU16360 with ACE (Angiotensin Converting Enzyme) inhibitory activity and application of the lactobacillus helveticus IMAU16360 in fermented milk, and belongs to the field of microorganisms. The lactobacillus helveticus IMAU16360 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36567, the preservation time is November 11, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The commercial leavening agent PYS-010 and the lactobacillus helveticus IMAU16360 are compounded according to the ratio of 1: 1, the pH and acidity change trend of the compounded group in the storage period is consistent with that of a control group, the compounded group is fused into an existing process system, and an existing production line does not need to be replaced; the elasticity and viscosity of a single strain fermented product are improved, so that the product is fuller in taste; on the premise that the basic taste is not influenced, the fermented milk has ACE inhibitory activity; meanwhile, a relatively high level of viable count is maintained, and good market value is achieved.

The invention discloses a cow milk clear source small molecule peptide, the amino acid sequence of which is Trp-Thr-Pro-Tyr-Arg (WTPYR), and the molecular weight of which is 721.80 Da. The small molecule peptide disclosed by the invention has angiotensin converting enzyme (ACE) inhibitory activity, can be applied to preparation of preparations for preventing and treating hypertension, provides effective active ingredients for developing foods and products with antihypertensive efficacy and without side effects, and has a good application prospect. And the small molecule peptide has the characteristics of simple preparation and safety, and is suitable for industrial production and market popularization and application.

The invention provides a method for preparing inhalable targeted gold nanoparticles for accelerating pulmonary delivery and treating pulmonary inflammation. The method comprises the following steps: preparing plasmids; carrying out plasmid transformation; carrying out protein expression induction; carrying out protein purification; and the gold nanoparticles (Au (at) PEG-RBD NP) combined with the spikes RBD are prepared. Nanoparticles (NP) in air accumulate more readily in lungs with lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) than in healthy lungs and enter alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN (both are Spike receptors activated in ARDS hamsters). The nanoparticles (NP) treat tissue damage, oxidative stress, and inflammation more effectively than corticosteroids, and do not remain gold or create toxicity in the major organs one year after inhalation. The gold core can be used for inhibiting p38 alpha mitogen activated protein kinase and polo-like kinase 3. Similar therapeutic effects have been observed in hamsters suffering from hydrochloric acid induced ARDS. This self-therapeutic nanoparticle (NP), when combined with biomimetic and non-invasive delivery, provides a safe, efficient, and targeted treatment for lung inflammation.

The invention belongs to the technical field of development of plant-derived bioactive peptides, and discloses a preparation method and application of a moringa seed antihypertensive polypeptide. Moringa seed polypeptide with the activity of inhibiting angiotensin converting enzyme (ACE) is separated and purified from moringa seed crude protein, nine moringa seed ACE inhibitory peptides with brand-new sequences and the effect of reducing blood pressure are finally obtained through structural identification, activity screening and solid-phase synthesis, sequence modification is conducted on polypeptide PLVRRAIY with the highest activity, and the trypsin enzymolysis resistance of the polypeptide PLVRRAIY is improved. Molecular level and animal experiments show that both the original peptide PLVRRAIY and the modified peptide PPVQQAIY have significant ACE inhibitory activity and antihypertensive effect, the trypsin degradation resistance of the modified peptide in the gastrointestinal tract environment is enhanced, the stability is significantly improved, and a new resource is provided for development of natural antihypertensive polypeptide drugs.

The present application relates to the technical field of polypeptide complex, and discloses an almond peptide-polyphenol complex and application thereof, wherein the almond peptide-polyphenol complex is obtained by compounding almond peptide and polyphenol, the amino acid sequence of the almond peptide from N-terminal to C-terminal is FPWLQ, and the molecular weight is 689.80 Da; the polyphenol is chlorogenic acid.The present application determines the inhibitory activity of the almond peptide-polyphenol complex on angiotensin converting enzyme, and the results show that the enzyme inhibitory activity of the complex is greatly improved compared with single almond peptide and polyphenol substance, which proves that the complex has good enzyme inhibitory activity and can be effectively applied to the development of antihypertensive drugs, realizes high value-added utilization of almond resources, and has important significance for promoting the sustainable development of the almond industry.

This angiotensin-converting enzyme inhibitor and this blood pressure-lowering agent contain a compound represented by formula (I) as an active ingredient. These beverages and food products for inhibiting an angiotensin-converting enzyme and these beverages and food products for lowering blood pressure are characterized by containing a compound represented by formula (I). As a result, provided are an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent that have an excellent angiotensin-converting enzyme-inhibiting effect and blood pressure-lowering effect. Furthermore, provided are beverages and food products suitable for inhibition of an angiotensin-converting enzyme and lowering of blood pressure.

The invention discloses an angiotensin converting enzyme inhibitory peptide screening method and system based on machine learning, and belongs to the technical field of bioinformatics. The angiotensin converting enzyme inhibitory peptide screening method based on machine learning comprises the following steps: step 1, constructing a peptide sequence data set, wherein the data set comprises known ACE inhibitory peptides and non-inhibitory peptides; 2, extracting multi-dimensional features from the peptide sequence, wherein the multi-dimensional features comprise physicochemical property features and sequence composition features; 3, training and optimizing a machine learning model by using the multi-dimensional features to obtain an ACE inhibitory peptide prediction model; and 4, performing activity prediction and virtual screening on a to-be-screened peptide sequence by using the ACE inhibitory peptide prediction model to obtain candidate ACE inhibitory peptides. According to the method, the multi-dimensional physicochemical and sequence characteristics of the peptide sequence are extracted, and the XGBoost machine learning prediction model is constructed and optimized, so that high-throughput virtual screening of 2-5 peptides can be realized, and the high-activity ultra-short ACE inhibitory peptide is efficiently explored.

The invention relates to a bifunctional peptide from cyclina sinensis, and belongs to the technical field of polypeptides. The amino acid sequence of the bifunctional peptide disclosed by the invention is His-Tyr-Pro-Gly-Gln-Pro-Tyr, and the amino acid sequence of the bifunctional peptide disclosed by the invention is as shown in the specification. The invention relates to an oligopeptide with alpha-glucosidase inhibitory activity and ACE (angiotensin converting enzyme) inhibitory activity. The invention also discloses a preparation method of the bifunctional peptide. The bifunctional peptide can also be synthesized by adopting a peptide synthesis method or a synthesis and modification method. The bifunctional peptide provided by the invention takes protein from marine cyclina sinensis as a starting point, is cut into active peptide with a specific sequence structure through control of cutting conditions of protease, has remarkable alpha-glucosidase inhibitory activity and angiotensin converting enzyme (ACE) inhibitory activity, has ICvalues of 0.4662 mg / mL and 0.09976 mg / mL respectively, and can be used for preparing the marine cyclina sinensis bifunctional peptide. Therefore, the tea has double physiological functions of reducing blood sugar and blood pressure. The bifunctional peptide provided by the invention can be used for preparing medicines or health-care foods for reducing blood sugar and / or blood pressure, has a clear sequence structure and dual biological activity, and provides a new way for developing multifunctional ocean-derived peptide products.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

The utility model belongs to the technical field of ACE (Angiotensin Converting Enzyme) inhibiting factor extraction, and particularly relates to a device for extracting ACE inhibiting factors in fructus aurantii, which comprises a fixing plate, a first fixing frame fixedly mounted on the front side of the fixing plate, a crushing kettle fixedly mounted on the inner side of the first fixing frame, and a second fixing frame fixedly mounted on the front side of the fixing plate, a second fixing frame is fixedly mounted on the front side of the fixing plate, an extraction tank is fixedly mounted on the inner side of the second fixing frame, a third fixing frame is fixedly mounted on the front side of the fixing plate, a filter press is fixedly mounted on the inner side of the third fixing frame, and a fourth fixing frame is fixedly mounted on the front side of the fixing plate. According to the device, materials can be added to the inner side of the crushing kettle through the feeding device to be crushed, the crushed materials can enter the inner side of the extraction tank and are added to the extraction volume, the stirring rod can be controlled to stir in the extraction process, and after stirring is completed, liquid can be conveyed to the inner side of the filter press through the liquid conveying pipe to be filtered.

The present application provides a kind of yeast peptide and its preparation method and application.The yeast peptide provided by the present application contains the following sequence peptide segment: phenylalanine-valine-alanine-leucine-proline, valine-leucine-isoleucine-leucine-lysine and alanine-glycine-leucine-threonine-leucine.The present application provides angiotensin converting enzyme (ACE) inhibitory activity and in vivo blood pressure lowering activity.

A method for preparing inhalable targeted gold nanoparticles for accelerated lung delivery and treating lung inflammation is provided. The method includes preparing plasmids; performing plasmids transformation; performing protein expression induction; performing protein purification; and preparing spike RBD-conjugated gold nanoparticles (Au@PEG-RBD NPs). The airborne NP preferentially accumulates in lungs with lipopolysaccharides-induced ARDS to healthy lungs and enters alveolar epithelial cells that express angiotensin converting enzyme (ACE) 2 and L-SIGN, both Spike receptors activated in ARDS hamsters. The NP treats tissue injury, oxidative stress, and inflammation more effectively than corticosteroids, without gold retention in major organs or toxicity 1-year post-inhalation. The gold core blocks p38α mitogen-activated protein kinase and polo-like kinase 3. Similar efficacy is observed in hamsters with hydrochloric acid-induced ARDS. The self-therapeutic NPs, when combined with bioinspiration and non-invasive delivery, provide a safe, effective, and targeted treatment for lung inflammation.

The present application belongs to the field of bioactive peptides. The present application provides an angiotensin converting enzyme inhibitory peptide and a screening method and application thereof, and the amino acid sequence of the inhibitory peptide is GKGLW and / or GDGLKW. The screening method of the inhibitory peptide of the present application uses soybean protein as raw material, adopts targeted alkaline protease and chymotrypsin double enzymolysis technology for preparation and screening, realizes rapid screening of ACE inhibitory peptides, and provides experimental basis for structure-activity relationship. The inhibitory peptide has strong blood pressure lowering activity, high safety and no toxic side effects. The determination of the stability of the digestive tract shows that the inhibitory peptide has good gastrointestinal stability in the gastrointestinal digestion, and can still maintain good activity after entering the blood.

The application provides a scomber ACE inhibitory peptide as well as a preparation method and application thereof, and relates to the technical field of ACE inhibitory peptides.The scomber ACE inhibitory peptide provided by the application comprises an amino acid sequence as shown in SEQ ID NO.1 or SEQ ID NO.2.Through papain enzymolysis, ultrafiltration, gel chromatography, liquid chromatography-tandem mass spectrometry sequence identification and QSAR modeling, the application improves the working efficiency of ACE inhibitory peptide screening, prepares and screens scomber ACE inhibitory peptides with high angiotensin converting enzyme inhibitory effect, and the scomber ACE inhibitory peptides can be used for developing new antihypertensive drugs, and have a wide application prospect.